Loading cancer entity…
Loading cancer entity…
Clinical trials
190 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03620032 | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses(DIPG) | unknown | Phase 2 | 54 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03932981 | First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression(TEMOTRAD01) | unknown | Phase 2 | 60 | Assistance Publique - Hôpitaux de Paris |
| 1 |
| Sep 10, 2021 |
| clinicaltrials |
| NCT04668508 | Anlotinib to Malignant Brainstem Glioma | unknown | Phase 2 | 25 | Zhejiang Cancer HospitalOTHER | 1 | Dec 16, 2020 | clinicaltrials |
| NCT02672241 | Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children | unknown | Phase 2 | 30 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02233049 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication(BIOMEDE) | unknown | Phase 2 | 250 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT01952769 | Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma | unknown | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Sep 13, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Dec 6, 2023source: clinicaltrials